Postoperative dendritic cell vaccine plus activated T-cell transfer improves the survival of patients with invasive hepatocellular carcinoma

References

• Imamura H, Matsuyama Y, Tanaka E, Ohkubo T, Hasegawa K, Miyagawa S, Sugawara Y, Minagawa M, Takayama T, Kawasaki S, et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol 2003; 38:200 - 7; http://dx.doi.org/10.1016/S0168-8278(02)00360-4; PMID: 12547409
   PubMed Web of Science ®Google Scholar
• Takayama T, Sekine T, Makuuchi M, Yamasaki S, Kosuge T, Yamamoto J, Shimada K, Sakamoto M, Hirohashi S, Ohashi Y, et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet 2000; 356:802 - 7; http://dx.doi.org/10.1016/S0140-6736(00)02654-4; PMID: 11022927
   PubMed Web of Science ®Google Scholar
• Engell-Noerregaard L, Hansen TH, Andersen MH, Thor Straten P, Svane IM. Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters. Cancer ImmunolImmunother 2009; 58:1 - 14; http://dx.doi.org/10.1007/s00262-008-0568-4; PMID: 18719915
   PubMedGoogle Scholar
• Shimizu K, Kotera Y, Aruga A, Takeshita N, Takasaki K, Yamamoto M. Clinical utilization of postoperative dendritic cell vaccine plus activated T-cell transfer in patients with intrahepatic cholangiocarcinoma. J HepatobiliaryPancreatSci 2012; 19:171 - 8; http://dx.doi.org/10.1007/s00534-011-0437-y; PMID: 21874278
   PubMedGoogle Scholar
• Liu S, Zhang H, Gu C, Yin J, He Y, Xie J, Cao G. Associations between hepatitis B virus mutations and the risk of hepatocellular carcinoma: a meta-analysis. J Natl Cancer Inst 2009; 101:1066 - 82; http://dx.doi.org/10.1093/jnci/djp180; PMID: 19574418
   PubMed Web of Science ®Google Scholar
• Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J ClinOncol 2009; 27:1485 - 91; http://dx.doi.org/10.1200/JCO.2008.20.7753; PMID: 19224838
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, et al, SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359:378 - 90; http://dx.doi.org/10.1056/NEJMoa0708857; PMID: 18650514
   PubMed Web of Science ®Google Scholar
• Zhang CH, Xu GL, Jia WD, Ge YS. Effects of interferon alpha treatment on recurrence and survival after complete resection or ablation of hepatocellular carcinoma: a meta-analysis of randomized controlled trials. Int J Cancer 2009; 124:2982 - 8; http://dx.doi.org/10.1002/ijc.24311; PMID: 19296539
   PubMed Web of Science ®Google Scholar
• Yoshida H, Shiratori Y, Kudo M, Shiina S, Mizuta T, Kojiro M, Yamamoto K, Koike Y, Saito K, Koyanagi N, et al. Effect of vitamin K2 on the recurrence of hepatocellular carcinoma. Hepatology 2011; 54:532 - 40; http://dx.doi.org/10.1002/hep.24430; PMID: 21574174
   PubMed Web of Science ®Google Scholar
• Chen T-T. Statistical issues and challenges in immuno-oncology. J Immunother Cancer 2013; 1:18; http://dx.doi.org/10.1186/2051-1426-1-18
   PubMedGoogle Scholar
• Ogi C, Aruga A. Clinical evaluation of therapeutic cancer vaccines. Hum VaccinImmunother 2013; 9:1049 - 57; http://dx.doi.org/10.4161/hv.23917; PMID: 23454867
   PubMed Web of Science ®Google Scholar
• Cheever MA, Higano CS. PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine. Clin Cancer Res 2011; 17:3520 - 6; http://dx.doi.org/10.1158/1078-0432.CCR-10-3126; PMID: 21471425
   PubMed Web of Science ®Google Scholar
• Aruga A, Takeshita N, Kotera Y, Okuyama R, Matsushita N, Ohta T, Takeda K, Yamamoto M. Long-term vaccination with multiple peptides derived from cancer-testis antigens can maintain a specific T-cell response and achieve disease stability in advanced biliary tract cancer. Clin Cancer Res 2013; 19:2224 - 31; http://dx.doi.org/10.1158/1078-0432.CCR-12-3592; PMID: 23479678
   PubMed Web of Science ®Google Scholar
• Matsushita N, Aruga A, Inoue Y, Kotera Y, Takeda K, Yamamoto M. Phase I clinical trial of a peptide vaccine combined with tegafur-uracil plus leucovorin for treatment of advanced or recurrent colorectal cancer. Oncol Rep 2013; 29:951 - 9; PMID: 23314271
   PubMed Web of Science ®Google Scholar
• Kono K, Iinuma H, Akutsu Y, Tanaka H, Hayashi N, Uchikado Y, Noguchi T, Fujii H, Okinaka K, Fukushima R, et al. Multicenter, phase II clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancer-testis antigens. J Transl Med 2012; 10:141; http://dx.doi.org/10.1186/1479-5876-10-141; PMID: 22776426
   PubMed Web of Science ®Google Scholar
• Chen IP, Ariizumi S, Nakano M, Yamamoto M. Positive glypican-3 expression inearly hepatocellular carcinoma predicts recurrence after hepatectomy. J Gastroenterol 2013; (Forthcoming); http://dx.doi.org/10.1007/s00535-013-0793-2
   Web of Science ®Google Scholar
• Sawada Y, Yoshikawa T, Nobuoka D, Shirakawa H, Kuronuma T, Motomura Y, Mizuno S, Ishii H, Nakachi K, Konishi M, et al. Phase I trial of a glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma: immunologic evidence and potential for improving overall survival. Clin Cancer Res 2012; 18:3686 - 96; http://dx.doi.org/10.1158/1078-0432.CCR-11-3044; PMID: 22577059
   PubMed Web of Science ®Google Scholar
• Koike N, Pilon-Thomas S, Mulé JJ. Nonmyeloablative chemotherapy followed by T-cell adoptive transfer and dendritic cell-based vaccination results in rejection of established melanoma. J Immunother 2008; 31:402 - 12; http://dx.doi.org/10.1097/CJI.0b013e31816cabbb; PMID: 18391755
   PubMed Web of Science ®Google Scholar
• Matsushita N, Pilon-Thomas SA, Martin LM, Riker AI. Comparative methodologies of regulatory T cell depletion in a murine melanoma model. J Immunol Methods 2008; 333:167 - 79; http://dx.doi.org/10.1016/j.jim.2008.01.012; PMID: 18295790
   PubMed Web of Science ®Google Scholar
• Morse MA, Hobeika AC, Osada T, Serra D, Niedzwiecki D, Lyerly HK, Clay TM. Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines. Blood 2008; 112:610 - 8; http://dx.doi.org/10.1182/blood-2008-01-135319; PMID: 18519811
   PubMed Web of Science ®Google Scholar
• Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013; 369:134 - 44; http://dx.doi.org/10.1056/NEJMoa1305133; PMID: 23724846
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Tykodi SS, Chow LQM, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366:2455 - 65; http://dx.doi.org/10.1056/NEJMoa1200694; PMID: 22658128
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, Reed K, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013; 369:122 - 33; http://dx.doi.org/10.1056/NEJMoa1302369; PMID: 23724867
   PubMed Web of Science ®Google Scholar
• Ogi C, Aruga A. Immunological monitoring of anticancer vaccines in clinical trials. Oncoimmunology 2013; 2:e26012; http://dx.doi.org/10.4161/onci.26012; PMID: 24083085
   PubMed Web of Science ®Google Scholar
• Elliott RL, Head JF. Adjuvant breast cancer vaccine improves disease specific survival of breast cancer patients with depressed lymphocyte immunity. SurgOncol 2013; 22:172 - 7; http://dx.doi.org/10.1016/j.suronc.2013.05.003; PMID: 23791552
   PubMed Web of Science ®Google Scholar
• Chang AE, Aruga A, Cameron MJ, Sondak VK, Normolle DP, Fox BA, Shu S. Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2. J ClinOncol 1997; 15:796 - 807; PMID: 9053507
   PubMed Web of Science ®Google Scholar
• Kandalaft LE, Powell DJ Jr., Chiang CL, Tanyi J, Kim S, Bosch M, Montone K, Mick R, Levine BL, Trigian DA, et al. Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccin-primed ex vivo co-stimulated T cells in recurrent ovarian cancer. OncoImmunlogy 2013; 2:1 - 9
   Google Scholar
• Galon J, Pagès F, Marincola FM, Thurin M, Trinchieri G, Fox BA, Gajewski TF, Ascierto PA. The immune score as a new possible approach for the classification of cancer. J Transl Med 2012; 10:1; http://dx.doi.org/10.1186/1479-5876-10-1; PMID: 22214470
   PubMed Web of Science ®Google Scholar